ArticleBMC pharmacology & toxicology2025
Preventive effects of crocin and meloxicam on morphine withdrawal symptoms in mice: behavioral and biochemical insights.
Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Crosstalk Between Glycinergic and N-Methyl-D-Aspartate Receptor-Mediated Glutamatergic Transmission in Behaviours Associated with Opioid Use Disorder.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe development of opioid-induced dependency is associated with several mechanisms, including oxidative stress, increase in inflammatory cytokines, and the activation of the glutamatergic system. This study investigates the effects of crocin, a bioactive compound from saffron, and meloxicam, a non-steroidal anti-inflammatory drug, on morphine withdrawal symptoms in male albino mice.
methodsTen groups, each consisting of nine mice, were randomly assigned to receive different treatments once daily for four days. On the fourth day, to assess the impact of the drugs on morphine dependency, naloxone was administered two hours after the final morphine injection. Withdrawal symptoms, specifically the frequency of jumping and standing on feet, were recorded over a 30-minute observation period for each mice. Additionally, to evaluate the effects of these drugs on pro-inflammatory cytokines, blood samples were collected from the animals' hearts, and tests for TNF-α levels were conducted.
resultsBehavioral assessments following naloxone-precipitated withdrawal showed that crocin and meloxicam (20 mg/kg) significantly reduced withdrawal behaviors, including jumping and standing. Additionally, serum TNF-α levels were significantly decreased in groups treated with crocin, indicating its potential anti-inflammatory effects.
conclusionThese findings indicate that crocin and meloxicam could potentially mitigate morphine withdrawal symptoms in mice, underscoring their promising therapeutic applications in the management of opioid dependence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.